NEW YORK / May 08, 2024 / Business Wire / Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, today announced that Chief Financial Officer, Scott Blackley, is scheduled to present and provide a business update at the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024 at approximately 8:40 AM PT (11:40 AM ET) in Las Vegas, NV.
All interested parties are invited to listen to a live webcast of the fireside chat by visiting www.ir.hioscar.com and selecting the “Events & Presentations” link. Following the presentation, a webcast replay will be available on Oscar’s investor relations website for a period of 90 days.
About Oscar Health
Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the healthcare system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of over 1.4 million members, as of March 31, 2024. We offer Individual & Family and Small Group plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor healthcare to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.
Last Trade: | US$16.66 |
Daily Change: | -0.58 -3.36 |
Daily Volume: | 9,434,491 |
Market Cap: | US$3.720B |
August 06, 2025 July 22, 2025 May 07, 2025 February 04, 2025 November 07, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load